In B2C business registered healthy volume growth, driven by increased throughput from the expanded center network. B2B volumes also grew, supported by higher wallet share and new customer acquisition, backed by improved service quality and delivery levels.

The company said EBITDA margins improved on a YoY basis in line with guidance. On quarter-on-quarter basis, margins remained largely stable. During the Q4 earnings call, promoter Ameer Shah said the company has guided for a sustainable group EBITDA margin of 27%–28% over the next three years.

Metropolis Healthcare is India’s second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics.

The company’s consolidated net profit rose 74.67% to Rs 50.90 crore on 22.99% increase in revenue from operations to Rs 424.68 crore in Q4 FY26 over Q4 FY25.